Published mark
Lilly (Eli)
ELI LILLY & Co
NYSE: LLY. Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:ed5c886b-f007-4eec-951c-0141de4aae25
- SEC CIK
- 0000059478
- Website
- www.lilly.com Open
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 15, 2026
- Newest evidence
- May 3, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- David RicksChair, President, and Chief Executive Officer (CEO)
- Chair
- David RicksLead independent: Juan R. Luciano
- Independent
- Not published13 directors published
- Published claims
- 595 distinct sources
- Evidence records
- 310 pinned
- Source conflicts
- 0None open
Built from 5 distinct sources and 31 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
Carolyn R. Bertozzi, Ph.D. seat on Lilly (Eli), effective 2026-03-20.
EffectiveEffective Mar 20, 2026E4
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Executive Vice President and President, Lilly Immunology | Adrienne Brown | Not captured | unknown | Source reportedE16 |
| Executive Vice President, General Counsel and Secretary | Anat Hakim | Not captured | unknown | Source reportedE17 |
| Executive Vice President and President, Lilly Neuroscience | Carole Ho | Not captured | unknown | Source reportedE18 |
| Executive Vice President, Chief Scientific and Product Officer and President, Lilly Research Laboratories | Daniel Skovronsky | Not captured | unknown | Source reportedE19 |
| Chair, President, and Chief Executive Officer (CEO) | David Ricks | Not captured | unknown | Source reportedE20 |
| Executive Vice President and Chief Information and Digital Officer | Diogo Rau | Not captured | unknown | Source reportedE21 |
| Executive Vice President and President, Manufacturing Operations | Edgardo Hernandez | Not captured | unknown | Source reportedE22 |
| Executive Vice President, Chief People Officer | Eric Dozier | Not captured | unknown | Source reportedE23 |
| Executive Vice President and President, Lilly USA and Global Customer Capabilities | Ilya Yuffa | Not captured | unknown | Source reportedE24 |
| Executive Vice President, President, Lilly Oncology and Head of Corporate Business Development | Jacob Van Naarden | Not captured | unknown | Source reportedE25 |
| Executive Vice President and President, Lilly Cardiometabolic Health | Kenneth Custer | Not captured | unknown | Source reportedE26 |
| Executive Vice President and Chief Financial Officer | Lucas Montarce | Not captured | unknown | Source reportedE27 |
| Executive Vice President, Global Quality | Melissa Seymour | Not captured | unknown | Source reportedE28 |
| Executive Vice President and President, Lilly International | Patrik Jonsson | Not captured | unknown | Source reportedE29 |
Board of directors
Evidence13 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Carolyn R. Bertozzi, Ph.D. | Independence not published | 2026 | None published | Source reportedE4 |
| David Ricks | Independence not publishedChair | 2017 | None published | Source reportedE3 |
| Gabrielle Sulzberger | Independence not published | 2026 | AuditAudit; Directors and Corporate GovernanceDirectors and Corporate Governance | Source reportedE5 |
| J. Erik Fyrwald | Independence not published | 2026 | Science and TechnologyTalent and CompensationTalent and Compensation; Science and Technology | Source reportedE6 |
| Jamere Jackson | Independence not published | 2026 | Audit, chairAudit · Chair; Directors and Corporate GovernanceDirectors and Corporate Governance | Source reportedE7 |
| Jon Moeller | Independence not published | 2024 | AuditAudit; Directors and Corporate GovernanceDirectors and Corporate Governance | Source reportedE8 |
| Juan R. Luciano | Independence not publishedLead Independent | 2026 | Directors and Corporate Governance, chairDirectors and Corporate Governance · Chair; Talent and CompensationTalent and Compensation | Source reportedE9 |
| Katherine Baicker, Ph.D. | Independence not published | 2026 | None published | Source reportedE10 |
| Kimberly Johnson | Independence not published | 2026 | Ethics and ComplianceTalent and CompensationTalent and Compensation; Ethics and Compliance | Source reportedE11 |
| Mary Lynne Hedley, Ph.D. | Independence not published | 2026 | None published | Source reportedE12 |
| Ralph Alvarez | Independence not published | 2026 | AuditAudit; Talent and Compensation · ChairTalent and Compensation, chair | Source reportedE13 |
| William G. Kaelin Jr., M.D. | Independence not published | 2026 | None published | Source reportedE14 |
| William Kaelin, Jr. | Independence not published | 2012 | Directors and Corporate GovernanceDirectors and Corporate Governance; Science and Technology · ChairScience and Technology, chair | Source reportedE15 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Jamere Jackson | Jamere Jackson, Gabrielle Sulzberger, Jon Moeller, Ralph Alvarez | Not described in the published record |
| Audit · Chair; Directors and Corporate Governance | Not published | Jamere Jackson | Not described in the published record |
| Audit; Directors and Corporate Governance | Not published | Gabrielle Sulzberger, Jon Moeller | Not described in the published record |
| Audit; Talent and Compensation · Chair | Not published | Ralph Alvarez | human_capital |
| Directors and Corporate Governance | Juan R. Luciano | Juan R. Luciano, Gabrielle Sulzberger, Jamere Jackson, Jon Moeller, William Kaelin, Jr. | Not described in the published record |
| Directors and Corporate Governance · Chair; Talent and Compensation | Not published | Juan R. Luciano | human_capital |
| Directors and Corporate Governance; Science and Technology · Chair | Not published | William Kaelin, Jr. | Not described in the published record |
| Ethics and Compliance | Not published | Kimberly Johnson | regulatory |
| Science and Technology | William Kaelin, Jr. | William Kaelin, Jr., J. Erik Fyrwald | Not described in the published record |
| Talent and Compensation | Ralph Alvarez | Ralph Alvarez, J. Erik Fyrwald, Juan R. Luciano, Kimberly Johnson | human_capital |
| Talent and Compensation; Ethics and Compliance | Not published | Kimberly Johnson | human_capital, regulatory |
| Talent and Compensation; Science and Technology | Not published | J. Erik Fyrwald | human_capital |
Committee RecordAudit: Chair Jamere Jackson; Members Jamere Jackson (Chair); Gabrielle Sulzberger; Jon Moeller; Ralph Alvarez
Committee AppointmentJamere Jackson: chair, Audit
Committee AppointmentGabrielle Sulzberger: member, Audit
Committee AppointmentJon Moeller: member, Audit
Committee AppointmentRalph Alvarez: member, Audit
Committee RecordDirectors and Corporate Governance: Chair Juan R. Luciano; Members Juan R. Luciano (Chair); Gabrielle Sulzberger; Jamere Jackson; Jon Moeller; William Kaelin, Jr.
Committee AppointmentJuan R. Luciano: chair, Directors and Corporate Governance
Committee AppointmentGabrielle Sulzberger: member, Directors and Corporate Governance
Committee AppointmentJamere Jackson: member, Directors and Corporate Governance
Committee AppointmentJon Moeller: member, Directors and Corporate Governance
Committee AppointmentWilliam Kaelin, Jr.: member, Directors and Corporate Governance
Committee RecordEthics and Compliance: Chair not stated; Members Kimberly Johnson
Committee AppointmentKimberly Johnson: member, Ethics and Compliance
Committee RecordScience and Technology: Chair William Kaelin, Jr.; Members William Kaelin, Jr. (Chair); J. Erik Fyrwald
Committee AppointmentWilliam Kaelin, Jr.: chair, Science and Technology
Committee AppointmentJ. Erik Fyrwald: member, Science and Technology
Committee RecordTalent and Compensation: Chair Ralph Alvarez; Members Ralph Alvarez (Chair); J. Erik Fyrwald; Juan R. Luciano; Kimberly Johnson
Committee AppointmentRalph Alvarez: chair, Talent and Compensation
Committee AppointmentJ. Erik Fyrwald: member, Talent and Compensation
Committee AppointmentJuan R. Luciano: member, Talent and Compensation
Committee AppointmentKimberly Johnson: member, Talent and Compensation
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerDavid Ricks, Chair, President, and Chief Executive Officer (CEO)
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceIndex MembershipS&P 500 (SPX)
Security ListingLLY (NYSE)
Security ListingLLY (SIX)
Index memberships1 membership attached to a specific security and listing.Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.
SPX
Source reportedAs of Oct 15, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
| Index | Security | Status | Effective | Verification | Source |
|---|---|---|---|---|---|
| S&P 500 (S&P Dow Jones Indices) | NYSE: LLY | current | Dec 31, 1970 | inferred | Slickcharts S&P 500 constituent table (public observation, not S&P DJI license) |
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameELI LILLY & Co
Entity StatusPublic listing published
Official Websitehttps://www.lilly.com
Published FactUS
Published FactIN
Published FactHealthcare
Published FactDrug Manufacturers
Published Facthttps://www.lilly.com
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Adrienne BrownExecutive Vice President and President, Lilly Immunologycompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:23
- Anat HakimExecutive Vice President, General Counsel and Secretarycompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:24
- Carole HoExecutive Vice President and President, Lilly Neurosciencecompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:25
- Daniel SkovronskyExecutive Vice President, Chief Scientific and Product Officer and President, Lilly Research Laboratoriescompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:26
- David RicksChair, President, and Chief Executive Officer (CEO)company:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:27, company:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:10
- Diogo RauExecutive Vice President and Chief Information and Digital Officercompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:28
- Edgardo HernandezExecutive Vice President and President, Manufacturing Operationscompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:29
- Eric DozierExecutive Vice President, Chief People Officercompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:30
- Ilya YuffaExecutive Vice President and President, Lilly USA and Global Customer Capabilitiescompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:31
- Jacob Van NaardenExecutive Vice President, President, Lilly Oncology and Head of Corporate Business Developmentcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:32
- Kenneth CusterExecutive Vice President and President, Lilly Cardiometabolic Healthcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:33
- Lucas MontarceExecutive Vice President and Chief Financial Officercompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:34
- Melissa SeymourExecutive Vice President, Global Qualitycompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:35
- Patrik JonssonExecutive Vice President and President, Lilly Internationalcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:36
- Carolyn R. Bertozzi, Ph.D.Directorcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:11
- Gabrielle SulzbergerDirectorcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:12
- J. Erik FyrwaldDirectorcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:13
- Jamere JacksonDirectorcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:14
- Jon MoellerDirectorcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:15
- Juan R. LucianoLead Independent Directorcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:16
- Katherine Baicker, Ph.D.Directorcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:17
- Kimberly JohnsonDirectorcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:18
- Mary Lynne Hedley, Ph.D.Directorcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:19
- Ralph AlvarezDirectorcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:20
- William G. Kaelin Jr., M.D.Directorcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:21
- William Kaelin, Jr.Directorcompany:ed5c886b-f007-4eec-951c-0141de4aae25:leadership_role:22
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 31 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 15, 2026. Cited by 8 Claims.
- E2ELI LILLY & Co Form 10-K (filed 2026-02-12). SEC filing. Retrieved Aug 29, 2026. Cited by 2 Claims.
- E3sec filing. Published Mar 20, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E4sec filing. Published Mar 20, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E5sec filing. Published Mar 20, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E6sec filing. Published Mar 20, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E7sec filing. Published Mar 20, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E8sec filing. Published Mar 20, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E9sec filing. Published Mar 20, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E10sec filing. Published Mar 20, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E11sec filing. Published Mar 20, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E12sec filing. Published Mar 20, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E13sec filing. Published Mar 20, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E14sec filing. Published Mar 20, 2026. Retrieved May 15, 2026. Cited by 1 Claim.
- E15sec filing. Published Mar 20, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E16LLY executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E17LLY executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E18LLY executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E19LLY executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E20LLY executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E21LLY executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E22LLY executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E23LLY executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E24LLY executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E25LLY executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E26LLY executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E27LLY executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E28LLY executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E29LLY executive roster sourcesec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
- E30board_seats. SEC EDGAR DEF 14A (2026-03-20). Cited by 21 Claims.
- E31Slickcharts S&P 500 constituent table (public observation, not S&P DJI license). index provider. Retrieved Sep 2, 2026. Cited by 1 Claim.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 15, 2026- Carolyn R. Bertozzi, Ph.D. seat on Lilly (Eli), effective 2026-03-20.
- Gabrielle Sulzberger seat on Lilly (Eli), effective 2026-03-20.
- J. Erik Fyrwald seat on Lilly (Eli), effective 2026-03-20.
- Jamere Jackson seat on Lilly (Eli), effective 2026-03-20.
- Juan R. Luciano seat on Lilly (Eli), effective 2026-03-20.
- Juan R. Luciano lead independent director of Lilly (Eli), effective 2026-03-20.
- Katherine Baicker, Ph.D. seat on Lilly (Eli), effective 2026-03-20.
- Kimberly Johnson seat on Lilly (Eli), effective 2026-03-20.
- Mary Lynne Hedley, Ph.D. seat on Lilly (Eli), effective 2026-03-20.
- Ralph Alvarez seat on Lilly (Eli), effective 2026-03-20.
- William G. Kaelin Jr., M.D. seat on Lilly (Eli), effective 2026-03-20.
- Audit · Chair; Directors and Corporate Governance committee of Lilly (Eli), effective 2026-03-20.
- Jamere Jackson member of Audit · Chair; Directors and Corporate Governance, effective 2026-03-20.
- Audit; Directors and Corporate Governance committee of Lilly (Eli), effective 2026-03-20.
- Gabrielle Sulzberger member of Audit; Directors and Corporate Governance, effective 2026-03-20.
- Audit; Talent and Compensation · Chair committee of Lilly (Eli), effective 2026-03-20.
- Ralph Alvarez member of Audit; Talent and Compensation · Chair, effective 2026-03-20.
- Directors and Corporate Governance · Chair; Talent and Compensation committee of Lilly (Eli), effective 2026-03-20.
- Juan R. Luciano member of Directors and Corporate Governance · Chair; Talent and Compensation, effective 2026-03-20.
- Talent and Compensation; Ethics and Compliance committee of Lilly (Eli), effective 2026-03-20.
- Kimberly Johnson member of Talent and Compensation; Ethics and Compliance, effective 2026-03-20.
- Talent and Compensation; Science and Technology committee of Lilly (Eli), effective 2026-03-20.
- J. Erik Fyrwald member of Talent and Compensation; Science and Technology, effective 2026-03-20.
- Jon Moeller seat on Lilly (Eli), effective 2024-01-01.
- Jon Moeller member of Audit; Directors and Corporate Governance, effective 2024-01-01.
- David Ricks seat on Lilly (Eli), effective 2017-01-01.
- David Ricks chairs board Lilly (Eli), effective 2017-01-01.
- William Kaelin, Jr. seat on Lilly (Eli), effective 2012-01-01.
- Directors and Corporate Governance; Science and Technology · Chair committee of Lilly (Eli), effective 2012-01-01.
- William Kaelin, Jr. member of Directors and Corporate Governance; Science and Technology · Chair, effective 2012-01-01.